Key EventTrading window closure announced for insiders
Key EventCompany states price movement is purely market-driven with no material pending information.
Medico Remedies Ltd (MEDICO)
·Next Day Close·-0.24%·₹32.67
Key EventAll seven AGM resolutions passed with requisite majorities.
ImpactShareholders endorsed current leadership and compensation, signaling confidence in management continuity.Sign up to read impact
Medico Remedies Ltd (MEDICO)
·Next Day Close·-3.28%·₹32.75
Key EventAGM adopts FY2026 financials and reappoints directors
ImpactShareholders approved director reappointments and compensation changes, signaling board continuity.Sign up to read impact
Medico Remedies Ltd (MEDICO)
·Next Day Close·+0.31%·₹42.5
Key EventSubmission of Annual Report 2025-26 and AGM notice for 32nd Annual General Meeting
ImpactShareholders must approve director reappointments and remuneration increases at the upcoming AGM, with no dividend proposed for FY 2025-26.Sign up to read impact
Medico Remedies Ltd (MEDICO)
·Next Day Close·+0.31%·₹42.5
Key EventBook closure announced for record date and AGM scheduled
Medico Remedies Ltd (MEDICO)
·Next Day Close·+0.31%·₹42.5
Key EventSubmission of Annual Report 2025-26 and notice of 32nd AGM
ImpactThe company reaffirmed leadership continuity with key appointments and modest growth, but no dividend was declared, signaling reinvestment focus.Sign up to read impact
Medico Remedies Limited (MEDICO)
·Next Day Close·-6.27%·₹45.01
Key EventBoard approved June 2026 quarterly results and director reappointments
ImpactLeadership continuity with new remuneration structure may affect governance perceptionSign up to read impact
Medico Remedies Limited (MEDICO)
·Next Day Close·-1.86%·₹47.48
Key EventMedico Remedies secures USD 1.41 million government contract in Dominican Republic
Medico Remedies Limited (MEDICO)
·Next Day Close·-3.29%·₹38.8
Medico Remedies Limited announced that CRISIL Ratings reaffirmed its long-term bank facilities rating at Crisil BBB-/Stable for Rs. 19 crore and short-term facilities at Crisil A3, with total rated facilities now amounting to ₹42 crores (up from Rs. 19 crore). The rating letter, received on June 25, 2026, confirms the reaffirmation and outlines surveillance practices, regulatory disclosures, and a validity period until March 31, 2027.
Sign up to read summary